Safety and efficacy of the farnesoid X receptor (FXR) agonist cilofexor in a proof-of-concept study in patients with compensated cirrhosis due to primary sclerosing cholangitis (PSC)

被引：0

作者：

Levy, Cynthia ^{[1
]}

Caldwell, Stephen ^{[2
]}

Mantry, Parvez ^{[3
]}

Luketic, Velimir ^{[4
]}

Landis, Charles ^{[5
]}

Huang, Jonathan ^{[6
]}

Mena, Edward ^{[7
]}

Maheshwari, Rahul ^{[8
]}

Rank, Kevin ^{[9
]}

Xu, Jun ^{[10
]}

Lu, Xiangyu ^{[10
]}

Lu, Xiaomin ^{[10
]}

Chung, Chuhan ^{[10
]}

Myers, Robert ^{[10
]}

Kowdley, Kris ^{[11
]}

机构：

[1] Univ Miami, Miller Sch, Coral Gables, FL 33124 USA

[2] Univ Virginia, Sch Med, Charlottesville, VA 22908 USA

[3] Liver Inst Methodist Dallas, Dallas, TX USA

[4] VCU Sch Med, Richmond, VA USA

[5] Univ Washington, Sch Med, Seattle, WA 98195 USA

[6] Univ Rochester, Sch Med & Dent, Rochester, NY 14627 USA

[7] Pasadena Liver Ctr, Pasadena, CA USA

[8] Piedmont Transplant Inst, Atlanta, GA USA

[9] MNGI Digest Hlth Northeast Minneapolis Clin, Minneapolis, MN USA

[10] Gilead Sci Inc, Foster City, CA USA

[11] Liver Inst Northwest, Seattle, WA USA

来源：

JOURNAL OF HEPATOLOGY | 2022年 / 77卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

THU455

引用

页码：S319 / S320

页数：2

共 25 条

[1] PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitis
Michael Trauner
Chuhan Chung
Kate Sterling
Xiangyu Liu
Xiaomin Lu
Jun Xu
Clare Tempany-Afdhal
Zachary D. Goodman
Martti Färkkilä
Atsushi Tanaka
Palak Trivedi
Kris V. Kowdley
Christopher L. Bowlus
Cynthia Levy
Robert P. Myers
[J]. BMC Gastroenterology, 23
[2] PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitis
Trauner, Michael
Chung, Chuhan
Sterling, Kate
Liu, Xiangyu
Lu, Xiaomin
Xu, Jun
Tempany-Afdhal, Clare
Goodman, Zachary D.
Faerkkilae, Martti
Tanaka, Atsushi
Trivedi, Palak
Kowdley, Kris V.
Bowlus, Christopher L.
Levy, Cynthia
Myers, Robert P.
[J]. BMC GASTROENTEROLOGY, 2023, 23 (01)
[3] Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSC
Trauner, Michael
Bowlus, Christopher L.
Gulamhusein, Aliya
Hameed, Bilal
Caldwell, Stephen H.
Shiffman, Mitchell L.
Landis, Charles
Muir, Andrew J.
Billin, Andrew
Xu, Jun
Liu, Xiangyu
Lu, Xiaomin
Chung, Chuhan
Myers, Robert P.
V. Kowdley, Kris
[J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2023, 21 (06) : 1552 - +
[4] SAFETY AND PRELIMINARY EFFICACY OF THE FARNESOID X RECEPTOR (FXR) AGONIST CILOFEXOR IN A 96-WEEK OPEN-LABEL EXTENSION OF A PHASE 2 STUDY OF PSC
Trauner, Michael H.
Gulamhusein, Aliya F.
Hameed, Bilal
Caldwell, Stephen
Shiffman, Mitchell L.
Landis, Charles
Muir, Andrew Joseph
Xu, Jun
Lu, Xiaomin
Chung, Chuhan
Myers, Robert P.
Bowlus, Christopher L.
Kowdley, Kris V.
[J]. HEPATOLOGY, 2021, 74 : 154A - 155A
[5] SAFETY AND EFFICACY OF MARALIXIBAT IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS: AN OPEN-LABEL PROOF-OF-CONCEPT STUDY
Bowlus, Christopher L.
Eksteen, Bertus
Cheung, Angela
Thorburn, Douglas
Moylan, Cynthia A.
Pockros, Paul J.
Forman, Lisa
Dorenbaum, Alejandro
Hirschfield, Gideon
Kennedy, Ciara
Gu, Joan
Apostol, George
Vig, Pamela
Levy, Cynthia
[J]. HEPATOLOGY, 2019, 70 : 764A - 765A
[6] Cilofexor in Patients With Compensated Cirrhosis Due to Primary Sclerosing Cholangitis: An Open-Label Phase 1B Study
Levy, Cynthia
Caldwell, Stephen
Mantry, Parvez
Luketic, Velimir
Landis, Charles S.
Huang, Jonathan
Mena, Edward
Maheshwari, Rahul
Rank, Kevin
Xu, Jun
Malkov, Vladislav A.
Billin, Andrew N.
Liu, Xiangyu
Lu, Xiaomin
Barchuk, William T.
Watkins, Timothy R.
Chung, Chuhan
Myers, Robert P.
Kowdley, Kris V.
[J]. CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2024, 15 (08)
[7] Letter to the Editor: Could Butyrate Be Incorporated With Farnesoid X Receptor Agonist Cilofexor to Enhance Primary Sclerosing Cholangitis Treatment? Reply
Trauner, Michael
Chung, Chuhan
Myers, Robert P.
Kowdley, Kris V.
[J]. HEPATOLOGY, 2020, 72 (04) : 1498 - 1499
[8] The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis
Trauner, Michael
Gulamhusein, Aliya
Hameed, Bilal
Caldwell, Stephen
Shiffman, Mitchell L.
Landis, Charles
Eksteen, Bertus
Agarwal, Kosh
Muir, Andrew
Rushbrook, Simon
Lu, Xiaomin
Xu, Jun
Chuang, Jen-Chieh
Billin, Andrew N.
Li, Georgia
Chung, Chuhan
Subramanian, G. Mani
Myers, Robert P.
Bowlus, Christopher L.
Kowdley, Kris V.
[J]. HEPATOLOGY, 2019, 70 (03) : 788 - 801
[9] Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis
Vuppalanchi, Raj
Caldwell, Stephen H.
Pyrsopoulos, Nikolaos
DeLemos, Andrew S.
Rossi, Simona
Levy, Cynthia
Goldberg, David S.
Mena, Edward A.
Sheikh, Aasim
Ravinuthala, Ravi
Shaikh, Farheen
Bainbridge, James D.
Parmar, Deven, V
Chalasani, Naga P.
[J]. JOURNAL OF HEPATOLOGY, 2022, 76 (01) : 75 - 85
[10] THE NONSTEROIDAL FARNESOID X RECEPTOR (FXR) AGONIST CILOFEXOR IMPROVES LIVER BIOCHEMISTRY IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS (PBC): A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED TRIAL
Kowdley, Kris V.
Minuk, Gerald Y.
Pagadala, Mangesh R.
Gulamhusein, Aliya
Swain, Mark Gordon
Neff, Guy W.
Zogg, Donald
Bowlus, Christopher L.
Agarwal, Kosh
Yoshida, Eric M.
Li, Yao
Li, Georgia
Chung, Chuhan
Subramanian, Mani
Myers, Robert P.
Sheikh, Aasim M.
Shiffman, Mitchell L.
Fickert, Peter
[J]. HEPATOLOGY, 2019, 70 : 31A - 32A

← 1 2 3 →